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Bradykinin improves postischaemic recovery in the 
rat heart: role of high energy phosphates, nitric 
oxide, and prostacyclin 
Peili Zhu, Christian E Zaugg, David Simper, Pius Hornstein, Peter R Allegrini, 
and Peter T Buser 
Objective: The aim was to define: (1) whether bradykinin administration during reperfusion improves 
postischaemic myocardial recovery; (2) whether high energy phosphate compounds are involved in the protective 
effects of bradykinin; and (3) whether bradykinin-induced release of prostacyclin and nitric oxide mediate the 
protective effects of bradykinin. Methods: In the Langendorff rat heart preparation, coronary flow, left 
ventricular developed pressure, and, using 3’P magnetic resonance spectroscopy, the high energy phosphate 
compounds phosphocreatine and B-ATP were assessed during 15 min of global ischaemia and 30 min of 
reperfusion. Administration of 10m7 M bradykinin was started before ischaemia and maintained throughout the 
experiment (BK-pre). This was compared to 10e7 M bradykinin given exclusively with reperfusion (BK-post). 
Then 10e7 M bradykinin was given simultaneously with lOi’ M Nw-nitro-L-arginine-methyl ester (BK-LNAME) 
or 10m5 M indomethacin (BK-indo). Results: In comparison to control hearts, BK-pre exerted a significant 
protective effect on the postischaemic recovery of coronary flow [71(5)% v 43(4)%, P < 0.051, left ventricular 
pressure [81(S)% v 42(5)%, P< 0.051, phosphocreatine [105(4)% v 67(g)%, P <0.05], and B-ATP [78(9)% v 
48(7)%, P<O.O5]. With BK-post, recovery of coronary flow [71(4)% v 43(4)%, P<O.O5] and left ventricular 
pressure [78(4)% v 42(5)%, P < 0.051 significantly improved; however the recovery of phosphocreatine [70(4)% 
v 67(g)%, NS] and B-ATP [58(2)% v 48(7)%, NS] was not different from control. When bradykinin and 
L-NAME or indomethacin was given the beneficial effects of bradykinin on ischaemic hearts were abolished. 
Conclusions: (1) Bradykinin improved postischaemic myocardial recovery when given before ischaemia or 
starting exclusively with reperfusion; (2) this was only partially related to a protective action on the high energy 
phosphate compounds during ischaemia; (3) the beneficial effects of bradykinin on ischaemic hearts are 
dependent from an unrestrained action of prostacyclin and nitric oxide. 
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C urrent therapy of acute myocardial infarction is aimed at early reperfusion by means of thrombolysis, angioplasty, and coronary bypass surgery in order to 
rescue myocardial tissue and to reduce ischaemic and 
reperfusion damage. A variety of drugs has been investigated 
for their ability to attenuate ischaemic myocardial damage 
and to improve postischaemic recovery. There is experi- 
mental evidence that angiotensin converting enzyme (ACE) 
inhibitors exert protective effects on the ischaemically 
threatened myocardium.’ ’ Three properties of ACE 
inhibitors may contribute to this protective effect. First, ACE 
inhibitors reduce the conversion of angiotensin I to 
angiotensin II, one of the most potent vasoconstrictive 
peptides.” Second, it has been proposed that some ACE 
inhibitors scavenge free oxygen radicals by the sulphydryl 
groups4 Third, ACE inhibitors reduce the bradykinin 
breakdown.5 The potential role of bradykinin in the pro- 
tective effect of ACE inhibitors in the ischaemic heart was 
recently supported by the abolition of this protection after 
coadministration of a bradykinin antagonist6 ’ 
The kinin precursors are (Y globulins called kininogens.* 
It has been shown that acute myocardial ischaemia is 
associated with a decrease in plasma kininogen and an 
increase in plasma kinins in rats.’ ‘O In humans, kinin levels 
in peripheral blood were found to increase soon after 
myocardial infarction. It was suggested that kinins released 
during myocardial infarction may have cardioprotective 
effects ” Furthermore, administration of bradykinin before L .
the onset of ischaemia has been shown to improve 
postischaemic recovery of left ventricular performance and 
to attenuate the severity of reperfusion arrhythmias in rat 
hearts6 However, it is not known whether the administration 
of bradykinin exclusively during reperfusion also leads to a 
beneficial effect. Furthermore, the mechanism behind the 
protective effects of bradykinin in ischaemic hearts is still 
unclear. It has been proposed that high energy phosphate 
compounds like ATP or phosphocreatine are involved in the 
protective effect of bradykinin. On the other hand, nitric 
oxide or prostacyclin may contribute to the protective effect 
of bradykinin because bradykinin could release these 
compounds. 
Our first objective was therefore to determine whether 
bradykinin administration during reperfusion improves the 
recovery of the ischaemic heart. Our second was to de- 
termine whether high energy phosphate compounds are 
involved in the protective effect of bradykinin. Thirdly, we 
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wanted to show whether bradykinin-induced release of 
prostacyclin or nitric oxide may mediate the protective effect 
of bradykinin. 
Petfused heart model 
Methods 
Male Sprague-Dawley rats weighing 250-330 g were anaesthetised by 
injection of sodium pentobarbitone (30 mg.kg-’ intraperitoneally) and 
heparinised (1000 IU.kg-’ intraperitoneally). The hearts were excised 
ranidlv throueh a midline stemotomv and Derfused at 37°C according 
to-a modified Langendozf method.” All hearts were perfused with a 
constant perfusion pressure of 90 cm HzO. As perfusate a modified 
Krebs-Henseleit solution was used containing (in mmollitre-‘): NaCl 
117, KC1 4.3, CaCl, 2.0, MgClz 1.2, KH,PO, 0.1, NaHCO, 25, EDTA 
0.5, and glucose 15, with insulin 10 unitslit&, pH 7.4, and gassed 
with 95% OZ and 5% C02.” The heart was maintained at 37°C by a 
thermostatic system throughout he experiment. A Grass SD 5 pulse 
generator was used throughout he experiment to pace the hearts at a 
constant frequency which was 20% above the spontaneous heart rate 
[264(SEM 34) beatsmin~‘].‘3 Eleven percent of all hearts were rejected 
because of delaved nrenaration resulting in a denressed left ventricular 
pressure development Lduring the eqmlibrium phase or persistent 
ventricular fibrillation following nostischaemic renerfusion. The 
number of rejected hearts was no’t significantly different between the 
treatment groups. All animal experiments were performed according to 
the guidelines of the ethics committee on animal research of the 
University Basel, Switzerland. 
Physiological measurements 
Left ventricular pressure was obtained from a cannula inserted through 
the left atria1 appendage into the left ventricular cavity and connected 
to a pressure transducer and a multitrace recorder. Left ventricular 
developed pressure was calculated as left ventricular systolic pressure 
minus left ventricular diastolic pressure. Coronary flow was determined 
by collecting the effluent from the right ventricular outflow tract.14 
“‘Phosphorus magnetic resonance spectroscopy (MRS) 
“P MRS of the isolated beating rat heart was obtained on a 4.7 Tesla 
horizontal 300 mm bore magnet (Bruker Spectrospin B-C 47/30). “P 
spectra were obtained at 8 I .O MHz with a spectral width of 5000 Hz. 
The pulse angle was 45” and the pulse duration was 50 ps with a 
repetition time of 1.0 s. Three hundred transients were accumulated at 
5 min intervals. The signal to noise ratio was 20: 1 for uhosnhocreatine. 
For each spectrum, the-characteristic peaks for phosphocreatine, the (Y, 
B, and y phosphate group of ATP, inorganic phosphate, and sugar 
monophosphates were identified.” After definition of the baseline, each 
spectrum and the corresponding areas were numerically integrated. 
Chemical shifts were referred to the resonance nosition of PCr.16 The 
intracellular pH (pHi) was calculated from the&chemical shift of the 
inorganic phosphate peak relative to phosphocreatine.” 
Experimental protocol 
Following 20 min drug-free perfusion under control conditions, 
allowing the hearts to stabilise (equilibrium period), the drugs were 
added to the perfusate for 30 min (preischaemic treatment period). 
Global ischaemia was then induced by stopping perfusion for 15 min 
(ischaemic period). The stopcock was re-opened and the heart 
reperfused under control condition for 30 min (reperfused period) 
(fig 1). Left ventricular pressure was continuously monitored, coronary 
flow was measured at 5 min intervals, and “P spectra were recorded 
durine 5 min neriods. 
The’ rats were randomly assigned to seven groups: (1) untreated 
control eroun (control. n= 8): (2) lo-’ M bradvkinin eiven nre- 
ischaemizally’ throughout he experiment (BK-pre, *n = 6); T3) lo-’ M 
bradykinin given postischaemically at the beginning of reperfusion 
(BK-post, n=6); (4) lo-’ M Nw-nitro-L-arginine methyl ester (L- 
NAME) given throughout he experiment (L-NAME, n = 5); (5) 10m5 M
indomethacin eiven throughout he exneriment (Indo. n = 5): (6) lo-’ M 
bradykinin and lOA M L-NAME given throughout he experiment (BK- 
LNAME. n = 7): (7) lo-’ M bradvkinin and lo-’ M indomethacin given 
throughout he’experiment (BK-ado, n = 6) (fig 1). 
Drugs 
Bradykinin, L-NAME, and indomethacin were from Sigma. 
Statistical analysis 
Results are reported as mean(SEM). The percent recovery was obtained 
compared to the values before ischaemia. Statistical analvsis between 
groups was performed with the one factor ANOVA Scheffe F test. 
Statistical analysis in the same group between equilibrium and 
preischaemic treatment period was performed with a paired Student’s 
t test. For all statistical analysis, the null hypothesis was rejected at the 
95% level, considering P < 0.05 significant. 
Results 
Absolute values 
At the end of the equilibrium phase, during which the hearts 
were allowed to stabilise, no significant changes were 
observed for coronary flow, left ventricular pressure, 
phosphocreatine, P-ATP, and pHi in any of the groups. There 
were no significant differences between the control group 
and all treatment groups. In the table absolute values of 
coronary flow and left ventricular pressure at the end of the 
equilibrium phase, the effects of bradykinin, L-NAME, and 
indomethacin on these variables, and the values after 30 min 
of postischaemic reperfusion are presented for all groups. 
Equilibrium Preischaemic treatment lschaemia Reperfusion 
20 min 30 min 15 min 30 min Group 
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Control (n=8) 
BK-pre (n=6) 
BK-post (n=6) 
L-NAME (n=5) 
lndo (n-5) 
BK-LNAME (n=7) 
BK-indo (n=6) 
*-+@K+LNAME> 
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Figure 1 The experimental protocol. Control group: Krebs-Henseleit solution throughout the experiment; BK-pre: bradykinin given 
preischaemically throughout the experiment; BK-post: bradykinin given postischaemically at the beginning of reperfusion; L-NAME: L-NAME 
given throughout the experiment; Indo: indomethacin given throughout the experiment: BK-LNAME: bradykinin and L-NAME given 
throughout the experiment; BK-indo: bradykinin and indomethacin given throughout the experiment. 
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Effect of bradykinin, L-NAME, and indomethacin on haemodynamic variables after 20 min of equilibrium, 30 min of preischaemic treatment, 
and 30 min of repefusion. Values are means(SEM). 
Coronary flow (ml.min-‘) 
Equilibrium Drug Repelfusion 
LVP (mm Hg) 
Equilibrium Drug Reperjiision 
Control (n = 8) lO.O(O.3) lO.O(O.3) 4.3(0.4) 8 l(2.6) 80(3.0) 33(3.7) 
BK-post (n = 6) lO.O(O.2) lO.O(O.2) 7.1(0.2)* 75(1.4) 74(1.6) 58(3.6)* 
BK-pre (n = 6) lO.O(O.2) 13.1(0.8)*t 9.4(1.2)* 76(1.1) 91(3.3)*t 75(8.8)* 
L-NAME (n = 5) 10.4(0.3) 5.5(0.2)*t 3.8(0.2) 80(0.9) 80(0.8) 19(4.7)* 
Indo (n = 5) 10.3(0.5) 10.6(0.4) 5.4(0.2) 82(0.5) 82(0.7) 40(6.8) 
BK-LNAME (n = 7) 10.2(0.6) 9.5(0.6) 5.6(0.2) 79(1.6) 89(2.1)*t 33(7.6) 
BK-indo (n = 6) 10.6(0.7) 12.0( 1.0) 5.5(0.7) 81(0.4) 93(0.8)*t 24(7.4) 
LVP = left ventricular developed pressure; BK-post = postischaemic administration of bradykinin; BK-pre = preischaemic administration of bradykinin; 
L-NAME = administration of L-NAME; Indo = administration of indomethacin; BK-LNAME = simultaneous administration of bradykinin and L-NAME; 
BK-indo = simultaneous administration of bradykinin and indomethacin 
*P < 0.05 v control group; tP < 0.05 v respective equilibrium period. 
Percent changes during ischaemia and repetfusion 
During the 20 min equilibrium period no significant changes 
were observed for coronary flow, left ventricular pressure, 
phosphocreatine, B-ATP, and pHi in any group. There were 
no significant differences between control group and all 
treatment groups. 
CONTROL GROUP 
After 15 min of ischaemia and 30 min of reperfusion, 
coronary flow, left ventricular pressure, phosphocreatine and 
B-ATP gradually recovered to 43(SEM 4)%, 42(5)%, 
67(8)%, and 48(7)%, respectively (figs 2-5). 
PREI~~HAEMI~ ADMINISTRATION OF BRADYHNIN (BK-PE) 
After 30 min of preischaemic treatment with bradykinin, the 
absolute values of coronary flow and left ventricular pressure 
in BK-pre group were significantly increased compared to 
the equilibrium period and to control (P < 0.05). 
After 15 min of ischaemia and 30 min of reperfusion, 
percent recovery of coronary flow [71(5)% v 43(4)%, 
P~O.051, left ventricular pressure [81(8)% v 42(5)%, 
P < 0.051, phosphocreatine [ 105(4)% v 67(g)%, P < 0.051, 
and B-ATP[78(9)% v 48(7)%, P~O.051 was significantly 
improved in BK-pre compared to control. Recovery from 
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Figure 2 Relative changes of coronary flow during ischaemia and 
reperfusion in control (n = S), and with preischaemic administra- 
tion of bradykinin (BK-pre, n = 6), postischaemic administration of 
bradykinin (BK-post, n = 6) simultaneous administration of 
bradykinin and indomethacin (BK-indo, n = 6), and simultaneous 
administration of bradykinin and L-NAME (BK-LNAME, n = 7) in 
rat hearts. 
*P < 0.05 v control; tP < 0.05 v BK-indo. 
intracellular acidosis, as assessed by pHi, was not different 
between BK-pre and control (figs 2-5). 
PosxscH~~MIc ADMINISTRATION OF BRADYKININ (BK-POST) 
Preischaemic values of coronary flow and left ventricular 
pressure were not different between BK-post and control. 
After 15 min of ischaemia and 30 min reperfusion, percent 
recovery of coronary flow [71(4)% v 43(4)%, P<O.O5] and 
left ventricular pressure [78(4)% v 42(5)%, P~O.051 was 
improved in BK-post compared to control. However, 
recovery of phosphocreatine [70(4)% v 67(8)%, NS] and 
B-ATP [58(2)% v 48(7)%, NS] was similar. There was 
no difference for recovery of coronary flow [71(5)% \-I 
71(4)%, NS] and left ventricular pressure [81(8)% v 78(4)%, 
NS] between BK-pre and BK-post. However, recovery 
of phosphocreatine [105(4)% v 70(4)%, P < 0.051 and 
B-ATP [78(9)% v 58(2)%, P <0.05] was improved with 
BK-pre (figs 2-5). 
PREISCHAEMIC ADMINISTRATION OF INDOMETHACIN (INDO) 
Preischaemic values of coronary flow and left ventricular 
pressure were not different between Indo and control. After 
15 min of ischaemia and 30 min reperfusion, percent 
recovery of coronary flow [51(3)% v 43(4)%, NS] and left 
0 5 10 15 5 10 15 20 25 30 
Time (min) 
Equil lschaemka Reperfusion 
Figure 3 Relative changes of left ventricular developed pressure 
during ischaemia and reperjusion in control (n = 8) and with 
preischaemic administration of bradykinin (BK-pre, n = 6), post- 
ischaemic administration of bradykinin (BK-post, n = 6), simul- 
taneous administration of bradykinin and indomethacin (BK-indo, 
n = 6) and simultaneous administration of bradykinin and L-NAME 
(BK-LNAME, n = 7) in rats hearts. 
*PC 0.05 v control; tP< 0.05 v BK-indo; $P< 0.05 v BK- 
LNAME. 
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Figure 4 Relative changes of phosphocreatine during ischaemia 
and repetjiision in control (n = S), and with preischaemic 
administration of bradykinin (BK-pre, n = 6j, postischaemic ad- 
ministration of bradykinin (BK-post, n = 6), simultaneous adminis- 
tration qf bradykinin and indomethacin (BK-indo, n = 6), and 
simultaneous administration of bradykinin and L-NAME (BK- 
LNAME, n = 7) in rat hearts. 
*PC 0.05 v control; iP < 0.05 v BK-indo; $P< 0.05 v BK- 
LNAME; pSP < 0.05 v BK-post. 
ventricular pressure [48(S)% v 42(5)%, NS] was similar to 
control (figs 2-5). 
SIMULTANEOUS ADMINISTRATION OF BRADYKININ AND 
INDOMETHACIN (BK-INDO) 
Preischaemic values of coronary flow showed a non- 
significant trend to be increased in BK-indo compared to 
control. However, preischaemic values of left ventricu- 
lar pressure were higher in BK-indo than in control. 
(P < 0.05). 
After 15 min of ischaemia and 30 min reperfusion, 
recovery of coronary flow [45(4)% v 43(4)%, NS], left 
ventricular pressure [29(9)% v 42(5)%, NS], phospho- 
creatine [53(5)% v 67(8)%, NS], and B-ATP [38(4)% v 
48(7)%, NS] with BK-indo was not different from control. 
Thus the improvement of recovery with bradykinin was 
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Figure 5 Relative changes of adenosine triphosphate (B-ATP) 
during ischaemia and reperjirsion in control (n = 8), and with 
preischaemic administration of bradykinin (BK-pre, n = 6), post- 
ischaemic administration of bradykinin (BK-post, n = 6), simul- 
taneous administration of bradykinin and indomethacin (BK-indo, 
n = 6), and simultaneous administration of bradykinin and L-NAME 
(BK-LNAME, n = 7) in rat hearts. 
*P < 0.05 v control: +Pc 0.05 v BK-indo; $P< 0.05 v BK- 
LNAME. 
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Figure 6 Relative changes of intracellular pH (pH,) during 
ischaemia and reperfusion in control (n = 8), and with pre- 
ischaemic administration of bradykinin (BK-pre, n = 6), postischae- 
mic administration of bradykinin (BK-post, n = 6), simultaneous 
administration of bradykinin and indomethacin (BK-indo, n = 6), 
and simultaneous administration of bradykinin and L-NAME (BK- 
LNAME, n = 7) in rat hearts. 
totally abolished with the combination of bradykinin and 
indomethacin (figs 2-5). 
PREISCHAEMI~ ADMINISTRATION OF L-NAME (L-NAME) 
Preischaemic administration of L-NAME caused a signifi- 
cant decrease of coronary flow, but left ventricular pressure 
remained unchanged. 
After 15 min of ischaemia and 30 min reperfusion, percent 
recovery of left ventricular pressure was 23(6)% (NS v 
control). Percent recovery of coronary flow was higher than 
in control (P < 0.05), but absolute values [3.8(0.2) ml.min’] 
indicated a persistent low flow ischaemia (figs 2-5). 
SIMULTANEOUS ADMINISTRATION OF BRADYKININ AND L-NAME 
(BK-LNAME) 
Preischaemic values of coronary how with BK-LNAME 
were not different from control. However, a slight increase 
in left ventricular pressure (P < 0.05) was observed. 
After 15 min of ischaemia and 30 min reperfusion, 
recovery of coronary flow [59(2)% v 43(4)%, NS], left 
ventricular pressure [40(9)% v 42(5)%, NS], phospho- 
creatine [73(4)% v 67(8)%, NS], B-ATP [58(6)% v 48(7)%, 
NS], and pH, [99(0.4)% v 99(0.4)%, NS] with BK-LNAME 
were not different from control. Thus the improvement of 
recovery with bradykinin was totally abolished with the 
combination of bradykinin and L-NAME (figs 2-5). 
Discussion 
In the present study, we first show that bradykinin ad- 
ministration during reperfusion improves the recovery of 
coronary flow and myocardial performance; second that high 
energy phosphate compounds are not directly involved in the 
protective effect of bradykinin; and third that bradykinin- 
induced release of nitric oxide and probably prostacyclin 
mediate the protective effect of bradykinin. 
Evidence for the first finding arises from the improved 
recovery of coronary flow and left ventricular pressure after 
postischaemic administration of bradykinin. In the present 
study, the effect of bradykinin on the postischaemic recovery 
was compared when bradykinin was given before ischaemia 
and exclusively after ischaemia, starting with reperfusion. 
662 Zhu, Zaugg, Simper, Hornstein, Allegrini, Buser 
Both BK-pre and BK-post improved the postischaemic 
recovery of coronary flow and myocardial performance. It 
has previously been reported that preischaemic administra- 
tion of bradykinin significantly reduced myocardial infarct 
size in the canine and rabbit model.6 7 Increased coronary 
flow, reduced enzymatic activities, a decreased incidence and 
duration of postischaemic reperfusion arrhythmias, and 
improved cardiodynamic indices in isolated rat hearts were 
also reported. I8 I9 In a pig model, bradykinin improved 
electrical stability two weeks after experimental myocardial 
infarction.” However, in all these previous studies 
bradykinin was given before the onset of ischaemia. 
Our results strongly support the hypothesis that bradykinin 
has protective effects on ischaemic and reperfused hearts. 
Second, we showed that high energy phosphate com- 
pounds are not directly related to the protective effect of 
bradykinin. In our study, an improved postischaemic 
recovery of mechanical performance concomitant with 
preservation of high energy phosphate compounds following 
preischaemic administration of bradykinin was observed. In 
contrast postischaemic administration of bradykinin resulted 
in an improved recovery of mechanical performance and 
coronary flow while the recovery of the high energy 
phosphate compounds was not different from control hearts. 
Therefore the cardioprotective effect of bradykinin was not 
directly related to the preservation of the high energy 
phosphate compounds. Some investigators previously pro- 
posed that an improvement of energy metabolism in 
ischaemic hearts may contribute to protective effects of 
bradykinin in the ischaemic heart. Following ischaemia and 
reperfusion, myocardial tissue levels of glycogen, ATP, and 
creatine phosphate were increased in bradykinin pretreated 
isolated rat hearts.5 I8 Our results in BK-pre group 
correspond very well with previously published data.27 
However, postischaemic administration of bradykinin re- 
sulted in an improved recovery of mechanical performance 
and coronary flow, while the recovery of the high energy 
phosphate compounds was not different from control hearts. 
Because of this discrepancy we speculate that the impaired 
breakdown of high energy phosphate compounds during 
ischaemia, when bradykinin is given preischaemically, may 
not be critical for the bradykinin related improvement of 
postischaemic recovery. On the other hand, in BK-indo and 
BK-LNAME there was faster depletion of ATP during 
ischaemia compared to BK-pre, suggesting that an un- 
restrained action of both nitric oxide (NO) and prostacyclin 
may contribute to the protective effect of bradykinin on ATP 
during ischaemia. 
Third, we showed that bradykinin-induced release of a 
cyclooxygenase product, probably prostacyclin, mediated the 
protective effect. Evidence for this finding arises from the 
results that administration of indomethacin alone did not 
change the postischaemic recovery but simultaneous ad- 
ministration of bradykinin and indomethacin completely 
abolished the beneficial effect of bradykinin on the recovery 
of coronary flow, left ventricular pressure, phosphocreatine, 
and B-ATP in ischaemic hearts. Consequently the recovery 
of these variables did not differ significantly from control but 
did differ from BK-pre. Some investigators previously 
proposed that the beneficial effect of bradykinin in 
myocardial ischaemia is probably mediated by stimulation of 
endothelial Bz receptors. This results in an increase in the 
intracellular calcium concentration and in the release of 
prostacyclin.’ The ability of bradykinin to stimulate 
prostacyclin generation from cultured endothelial cells is 
well recognised25 and this effect was inhibited in a dose 
dependent manner by the bradykinin receptor antagonist.26 
Prostacyclin given to isolated working rat hearts reduced 
ischaemia-reperfusion injury.27 Our results support these 
observations. It is suggested that cyclooxygenase products, 
probably prostacyclin, are important mediators involved in 
the protective effects of bradykinin on ischaemic hearts. 
Thus bradykinin-induced release of vasodilator cyclo- 
oxygenase products contributes to the cardioprotective 
effects of bradykinin. 
In addition, we showed that bradykinin-induced release of 
NO mediated the protective effect of bradykinin. Evidence 
for this arises from the finding that administration of 
L-NAME alone worsened the postischaemic recovery, and 
simultaneous administration of bradykinin and L-NAME 
abolished the beneficial effect of bradykinin on the recovery 
of coronary flow, left ventricular pressure, phosphocreatine, 
and B-ATP, which did not differ from control. Previous 
studies have shown that bradykinin is a potent endothelium 
dependent vasodilator in many vessels.‘l It can stimulate the 
release of NO from cultured endothelial cells*’ as well as 
from isolated guinea pig hearts.23 NO released from 
endothelial cells activates the haem protein soluble guanylyl 
cyclase in vascular smooth muscle cells and in platelets. 
The resulting increase in cyclic guanosine monophosphate 
inhibits smooth muscle contraction and platelet activation by 
reducing the intracellular concentration of free calcium. A 
recent study showed that this effect was blocked by the 
bradykinin B2 antagonist HOE140.24 In the present study, the 
improved postischaemic recovery of coronary flow reflects 
the dilator action of bradykinin, and the improved recovery 
of left ventricular pressure may result from the improved 
tissue perfusion. With simultaneous administration of brady- 
kinin and L-NAME the beneficial effects of bradykinin on 
recovery of coronary flow, left ventricular pressure, 
phosphocreatine, and B-ATP in ischaemic hearts were 
abolished. Therefore an unrestrained action of nitric oxide 
contributes to the cardioprotective effect of bradykinin. 
Our conclusions are: (1) bradykinin improves postischae- 
mic myocardial recovery when given before ischaemia or 
starting with reperfusion; (2) this beneficial effect is only 
partially related to the preservation of the high energy 
phosphate compounds; and (3) the beneficial effects of 
bradykinin on postischaemic myocardial recovery are 
dependent from an unrestrained action of nitrix oxide and 
prostacyclin. 
PZ is supported by the Swiss Foundation for Cardiology. CEZ is 
sunuorted bv a grant from Swiss National Science Foundation. PTB is 
a recipient of acareer development grant (SCORE) from the Swiss 
National Science Foundation. 
Key terms: ischaemia; reperfusion; myocardium; bradykinin; nitric 
oxide; prostacyclin; magnetic resonance spectroscopy; cardioprotective 
effect. 
Received 8 August 1994; accepted 20 December 1994. Time for 
primary review 28 days. 
1 Scholkens BA, Linz W. Cardiourotective effects of ACE 
inhibitors: experimental proof and clinical perspectives. Clin 
Physiol Biochem 1990;8(suppl 1):33-43. 
2 Gavras I, Gavras H. Cardioprotective potential of angiotensin- 
converting enzyme inhibitors. Clin Car&o1 1991;14(suppl IV): 
IV-68-71. 
3 Ondetti MA, Cushman D. Enzymes of the renin-angiotensin 
system and their inhibitions. Annu Rev Biochem 198251: 
283-308. 
4 Westlin W, Mullane K. Does captopril attenuate reperfusion- 
induced myocardial dysfunction by scavenging free radicals? 
Circulation 1988;77(suppl 1):3&9. 
Bradykinin in the repe@sed myocardium 663 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
Linz W, Scholkens BA, Influence of local converting enzyme 
inhibition on angiotensin and bradykinin effects in ischemic 
rat hearts. J Curdiovusc Pharmacol 1987;1O(suppl VII): 
S75-82. 
Linz W, Scholkens BA. Role of bradykinin in the cardiac effects 
of angiotensin-converting enzyme inhibitors. J Cardiovasc Phur- 
macol 1992;2O(suppl IX):S81-90. 
Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of 
myocardial infarct size in rabbits by ramiprilat: reversal by the 
bradykinin antagonist HOE 140. J Curdiovasc Pharmucol 1993; 
21:9961003. 
Muller-Ester1 W. Kininogens, kinins, and kinships. J Curdiovusc 
Phurmucol 1990;15(suppl VI):Sl-6. 
Mats&i T, Yoshida S. Sympathetically induced myocardial 
ischaemia causes the heart to release olasma kinin. Cardiovusc 
Res 1987;21:428-32. 
Baumgarten CR, Linz W, Kunkel G, Scholkens BA, Wiemer G. 
Rami@ilat increases bradykinin outflow from isolated hearts of 
rat. Br J Pharmacol 1993;108:293-5. 
Hashimoto K, Hamamoto H, Honda Y, Hirose M, Furukawa S, 
Kimura E. Changes in components of kinin system and 
hemodynamics in acute myocardial infarction. Am Heart J 
1978;95:619-26. 
Buser PT, Wagner S, Wu ST, et al. Verapamil preserves 
myocardial performance and energy metabolism in left ventricular 
hypertrophy following ischemia and reperfusion: phosphorus 31 
magnetic resonance spectroscopy study. Circulation 1989;80: 
183745. 
Zaugg CE, Zhu P, Simper D, Liischer TF, Allegrini PR, Buser PT. 
Differential effects of endothelin-1 on normal and postischemic 
reperfused myocardium. J Curdiovusc Phurmucol 1993;22(suppl 
VIII):S367-70. 
Buser PT, Wagner S, Wu S, Higgins CB, Wikman-Coffelt J. 
Protective effects of calcium antagonists on energy and substrate 
metabolism during ischemia and reperfusion. J Curdiovasc 
Pharmacol 1991;18(suppl X):S87-92. 
Buser PT, Auffermann W, Wu ST, Jasmin G, Parmley WW, 
W&man-Coffelt J. Dobutamine potentiates amrinone’s beneficial 
effects in moderate but not in advanced heart failure: “P-MRS in 
isolated hamster hearts. Circ Res 1990:66:747-53. 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
Buser PT, Wikman-Coffelt J, Wu ST, Derugin N, Parmley WW, 
Higgins CB. Postischemic recovery of mechanical performance 
and energy metabolism in the presence of left ventricular 
hypertrophy: a “p-MRS study. Circ Res 1990;66:73546. 
Gaddian DG, Radda GK, Richards RE, Seeley PJ. Biological 
applications of magnetic resonance. New York: Academic Press, 
1979. 
Linz W, Martorana PA, Scholkens BA. Local inhibition of 
bradykinin degradation in ischemic hearts. J Curdiovusc Phurmu- 
col 199O;lS(suppl VI):S99-109. 
Chahine R, Adam A, Yamaguchi N, Gaspo R, Regoli D, Nadeau 
R. Protective effects of bradykinin on the ischemic heart: 
implication of the B, receptor. Br J Pharmucol 1993;108: 
318-22. 
Tobe TJ, de LC, Tio RA, Be1 KJ, Mook PH, Wesseling H. In vivo 
effect of bradykinin during ischemia and reperfusion: improved 
electrical stability two weeks after myocardial infarction in the 
pig. J Curdiovusc Phurmucol 1991;17:60&7. 
Leipert B, Becker BF, Gerlach E. Different endothelial mechan- 
isms involved in coronarv resoonses to known vasodilators. Am J 
Physiol 1992;262:Hl6761-83. ’ 
Palmer RMJ, Ferrige AG. Nitric oxide release accounts for the 
biological activity of endothelium-derived relaxing factor. Nature 
1987;327:524d. 
Kelm M. Schrader J. Control of coronarv vascular tone bv nitric 
oxide. Ckc Res 1990;66:1561-75. ’ 
, 
Wiemer G, Schiilkens BA, Becker RHA, Busse R. Ramiprilat 
enhances endotbelial autacoid formation by inhibiting breakdown of 
endothelium-derived bradvkinin. Hwertension 1991:18:558-63. 
McIntyre TM, Zimmerman GA, S.M. P Cultured endothelial cells 
synthesize both platelet-activating factor and prostacyclin in 
response to histamine, bradykinin and adenosine triphosphate. J 
Clin Invest 1985;76:271-80. 
Hoffmann G, Pietsch R. Converting enzyme inhibition and 
vascular prostacyclin synthesis: effect of kinin receptor antagon- 
ism. Eur J Pharmacol 1990;178:79-83. 
Linz W, Martorana PA, Grotsch H, Bei-Yin Q. Antagonizing 
bradykinin obliterates the cardioprotective ffects of bradykinin 
and angiotensin-converting enzyme (ACE) inhibitors in ischemic 
hearts. Drug Dev Res 1990;19:393-408. 
